aPneumonia includes atypical pneumonia, bronchopulmonary aspergillosis, pneumonia, pneumonia haemophilus, pneumonia influenzal, pneumonia pneumococcal, pneumonia streptococcal, pneumonia viral, candida pneumonia, pneumonia bacterial, haemophilus infection, lung infection, pneumonia fungal, and Pneumocystis jirovecii pneumonia.
bUpper respiratory tract infection includes bronchiolitis, bronchitis, bronchitis viral, chronic sinusitis, fungal pharyngitis, influenza-like illness, laryngitis, nasopharyngitis, parainfluenzae virus infection, pharyngitis, respiratory tract infection, respiratory tract infection viral, rhinitis, sinusitis, tracheitis, upper respiratory tract infection, and upper respiratory tract infection bacterial.
cDyspnea includes dyspnea, dyspnea exertional, and dyspnea at rest.
7% of patients who received SARCLISA discontinued treatment
due to an adverse reaction (grades 1-4)1
Onset of IRRs was typically within 24 hours from the start of the infusion. IRRs were reported in 38% of patients treated with SARCLISA.
IRR=infusion-related reaction; Pd=pomalidomide and dexamethasone.Dosing